Full-Time
Posted on 9/30/2025
Medical diagnostic laboratory services provider
No salary listed
Essex, UK
In Person
The role requires working across three sites, including hospitals that operate 24-hours.
| , |
SYNLAB provides a full range of medical laboratory services for practicing doctors, clinics, and patients. Its diagnostic tests cover human medicine and are processed through a wide network of labs across 36 countries and four continents, making it a leading partner for laboratory diagnostics in Europe. Tests are performed in certified laboratories using standardized procedures to deliver fast, reliable, high-quality results that doctors use to diagnose and monitor conditions. SYNLAB differentiates itself through its large European footprint, integrated laboratory network, and scale, which enable consistent, timely diagnostics across many sites. The company’s goal is to support better patient care by expanding access to accurate and efficient laboratory testing.
Company Size
5,001-10,000
Company Stage
Acquired
Total Funding
$1.7B
Headquarters
Munich, Germany
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Wellness Program
Professional Development Budget
Cinven has completed the sale of an indirect minority stake in SYNLAB to Labcorp, a global leader in laboratory services. SYNLAB, a major player in medical diagnostics in Europe, achieved revenues of €2.62 billion in 2024. The companies plan to explore opportunities for Labcorp's specialty tests in Europe and potential collaborations. Labcorp, with nearly 70,000 employees, supported over 75% of new FDA-approved drugs in 2024.
Gómez-Acebo & Pombo has advised the Synlab Group, a leader in medical diagnostic services and specialized tests in Europe, in the sale of Synlab Spain to Eurofins Scientific (EUFI.PA).
Synlab is a medical diagnostic services and specialty testing provider.
EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze OutCinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow30.10.2024 / 07:32 CET/CESTThe issuer is solely responsible for the content of this announcement.Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in SYNLAB, alongside existing shareholders Cinven, Labcorp (subject to regulatory approval), and Qatar Holding LLC. The transaction is subject to regulatory approvals and is expected to close in early 2025. The acquiring entity of Elliott’s shareholding will be Ephios Bidco GmbH (“Ephios Bidco”), an entity controlled by funds managed and/or advised by Cinven and the majority shareholder of SYNLAB AG. Ephios Bidco currently holds approximately 86% of the SYNLAB share capital
SYNLAB agrees to sell its Spanish business to Eurofins.